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Abstract 
Desmoid tumors, also known as aggressive fibromatosis, are tumors of intermediate 
dignity, which grow slowly but are locally aggressive. These tumors do not metastasize 
but can be potentially life threatening when infiltrating vital structures. The therapy 
strategy consists of surgery, radiation and systemic therapy with non-steroidal anti-
inflammatory drugs, antiestrogen compounds and cytotoxic chemotherapy. We report 
on a 40-year-old male patient with advanced fibromatosis of the neck who has been 
treated with 7 cycles of polychemotherapy (adriablastin, ifosfamide and dacarbazine) 
followed by targeted therapy with imatinib. Tumor response was evaluated clinically and 
by magnetic resonance imaging. The tumor decreased significantly after the first cycle of 
chemotherapy and tumor-related symptoms declined. The response continued after 
switching to targeted therapy with imatinib, which is currently ongoing. The best 
treatment for this rare tumor remains under discussion. Doxorubicin and dacarbazine are 
frequently used agents. We included ifosfamide in our therapy, which is standard in the 
treatment of soft tissue tumors. The tyrosine kinase inhibitor imatinib seems to offer new 
possibilities and is currently investigated in randomized trials. We conclude that 
combination chemotherapy including doxorubicin, ifosfamide and dacarbazine in the 
treatment of aggressive fibromatosis should be considered for patients suffering from 
unresectable, advanced disease and clinical symptoms which require a rapid response to 
therapy.  
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Introduction 
Desmoid tumors, also known as aggressive fibromatosis, are tumors of intermediate 
dignity according to the 2002 WHO classification [1]. These tumors grow slowly but are 
locally aggressive and can be potentially life threatening when infiltrating vital structures. 
Desmoids are very rare neoplasms with an incidence of 2–4 cases per 1 million 
inhabitants per year and make up about 5% of all soft tissue tumors [2]. The exact 
pathogenesis remains unclear; trauma and surgery as well as endocrine and genetic 
factors seem to be implicated in the development of desmoid tumors.  
The therapy strategy for aggressive fibromatosis consists of local treatment with 
surgery and radiation [3, 4], systemic therapy with non-steroidal anti-inflammatory drugs 
(NSAIDs) [5], hormonal therapy [5] and chemotherapy [6–11, 14, 15].  
Small extra-abdominal tumors are potentially curative when treated with surgery with 
wide local excision and histopathologic negative margins. The optimal treatment strategy 
for advanced, inoperable desmoid tumors consists of the use of NSAIDs [5], hormonal 
therapy with antiestrogen compounds or progesterone [5] and cytotoxic chemotherapy 
including ifosfamide, doxorubicin, dacarbazine, methotrexate and vinblastine [6–11, 14, 
15]. Due to the rarity of the disease, no randomized trials are currently available 
comparing different chemotherapy regimens. The tyrosine kinase inhibitor imatinib 
shows promising results in first trials [12, 13].  
We report on a patient with an advanced desmoid tumor on the right side of the neck 
who was successfully treated with polychemotherapy followed by a targeted therapy with 
imatinib. 
Methods 
In October 2007, a 40-year-old male patient presented with an advanced tumor involving the right 
and left supraclavicular area and the upper thorax. The tumor was ulcerated, fetid and continuously 
bleeding (fig. 1a) and the mobility of the neck and head was severely constricted. The patient needed 
constant oral analgesic therapy, and due to the tumor bleeding with severe anemia, continuing 
administration of blood transfusions was necessary.  
The first occurrence of the lesion was 12 years ago. The patient noticed a solid painless tumor on the 
right side of the neck and underwent surgical excision. Histology revealed an aggressive fibromatosis. 
After tumor recurrence, no further operation or other local therapy was performed. Under systemic 
therapy with NSAIDs and 10 months of antiestrogen treatment with tamoxifen the tumor progressed.  
After giving written informed consent, the patient was treated with polychemotherapy including 
ifosfamide, adriablastin and dacarbazine (IFADIC). He received 40 mg/m
2 adriablastin on the first day 
and 1,500 mg/m
2 ifosfamide and 200 mg/m
2 dacarbazine daily for 4 days. After a febrile neutropenia, 
the dose of chemotherapy was consequently reduced to 75% and a granulocyte colony-stimulating 
factor (G-CSF) was given. No further neutropenia occurred with G-CSF support. Altogether, 7 cycles of 
polychemotherapy were administered according to the IFADIC-scheme. Due to a thrombosis of the 
right leg and the cumulative dose of adriablastin with regard to cardiotoxicity, the chemotherapy was 
discontinued. 
To obtain the tumor response, we started a therapy with imatinib, a selective tyrosine kinase 
inhibitor, 2 months after the last cycle of chemotherapy. Since May 2008, the patient has been receiving 
400 mg of imatinib daily orally without any severe side effects.  
Tumor response was evaluated clinically and by magnetic resonance imaging volumetry (MRI 
volumetry). MRI volumetry was performed using T2- and T1-weighted plain sequences after 
administration of gadolinium-diethylenetriaminepentaacetate. Tumor volume (in cubic centimeter, cc) 
was calculated by a slice-by-slice evaluation by the same radiologist. In addition, at each visit images of 
the tumor were taken to document the treatment response.  
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Results 
After 2 cycles of chemotherapy, MRI showed an extensive tumor at the right upper 
thorax aperture with 20.5 cm craniocaudal × 17.5 cm transversal × 13.5 cm sagittal and a 
total tumor volume of 2,345.09 cc (fig. 1d). Due to technical problems a comparison with 
the MRI before start of the therapy was not possible. The MRI volumetry after the fifth 
cycle confirmed the response (1,898.76 cc), which was observed by clinical examination. 
At the end of chemotherapy, the desmoid tumor decreased to 1,078.78 cc with a 
dramatically improvement of the clinical symptoms (fig. 1e). 
During the targeted therapy, we observed a continuous reduction of the tumor. After 
11 months the total volume was 931.47 cc. The last MRI volumetry was performed in July 
2009 and showed a tumor volume of 7,445.26 cc (fig. 1f). 
Clinical examination at each visit demonstrated a decrease of the tumor (fig. 1b, c) and 
clinical benefit with decline of tumor-related pain and an increased mobility in the neck. 
Discussion 
The role of chemotherapy in the treatment of advanced desmoid tumors is still under 
discussion. Due to the rarity of these lesions and the lack of clinical trials there is no 
standardized chemotherapy regime. 
Janinis et al. [14] published a systematic review with overall response rates to 
combination chemotherapy from 17 to 100% using doxorubicin, dacarbazine, 
methotrexate and vinca alkaloids. 
Methotrexate in combination with vinca alkaloids (vincristine and vinblastine) was 
used in different studies [6, 10, 15]. Azzarelli et al. [10] published a trial in which 30 
patients with advanced aggressive fibromatosis responded to low-dose methotrexate and 
vinblastine weekly for a median of 1 year. Combination of methotrexate with vinorelbine 
is mentioned as an alternative with the same outcome but potentially slightly less 
neurotoxicity [15]. 
The most commonly used treatment regimes included the combination of doxorubicin 
and dacarbazine, which lead to responses in about 75% of the cases [7–9, 11]. Common 
side effects of doxorubicin were acute and late cardiomyopathy and congestive heart 
failure. Patel et al. [8] reported death due to cardiomyopathy in a patient who received a 
cumulative dose of 1,000 mg/m
2 doxorubicin for the treatment of aggressive fibromatosis. 
Ifosfamide is a standard chemotherapy in the treatment of soft tissue sarcoma. Verrill 
et al. [16] showed chemosensitivity of fibromatosis cells to 4-hydroxy-ifosfamide (the 
active form of ifosfamide) in vitro. Successful treatment of 6 patients with the 
combination of ifosfamide and etoposide was reported by Okuno et al. [7].  
Table 1 shows an overview of reported chemotherapeutic regimes in the treatment of 
desmoid tumors. 
The tyrosine kinase inhibitor imatinib offers new possibilities in the treatment of 
aggressive fibromatosis. Imatinib is the standard first-line therapy for chronic myeloic 
leukemia and gastrointestinal stroma tumors. There are 2 prospective studies 
investigating imatinib for the treatment of aggressive fibromatosis [13, 14]. Preliminary  
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data was presented at the American Society of Clinical Oncology annual meeting in 2006 
and 2007 (table 2). 
Altogether, the treatment of advanced aggressive fibromatosis remains difficult. The 
reported patient had a massive advanced tumor and a significant limitation of the quality 
of life. Constant analgesic therapy and blood transfusions were necessary. We decided to 
start combination chemotherapy with the intention to achieve a quick response and 
improve clinical symptoms. Based on the treatment of soft tissue tumors, we combined 
ifosfamide to doxorubicin and dacarbazine and the patient achieved a clinical benefit after 
the first cycle and clinical response was observed at every further clinical visit.  
Although the desmoid tumor is cytological benign but locally aggressive and usually 
slowly growing, in some cases, an aggressive combination of chemotherapy is needed to 
obtain a quick response. Therefore the IFADIC-scheme could be a possible alternative for 
patients with advanced desmoids and clinical symptoms. Due to adequate supportive 
therapy side effects of chemotherapy are well manageable. As a limiting factor, the 
potential cardiotoxicity of doxorubicin must be mentioned.  
Conclusion 
The use of combination chemotherapy including doxorubicin, ifosfamide and 
dacarbazine in the treatment of aggressive fibromatosis should be considered for patients 
who suffer from unresectable, advanced disease. For stabilization of disease, further 
targeted therapy with imatinib presents a valid option. 
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Table 1. Combination chemotherapy in the treatment of aggressive fibromatosis 
Study No.  of 
patients 
Chemotherapeutic agents  Response  Duration 
of therapy  
Follow- 
up 
Weiss and 
Lackman 1989 
[6] 
08  vinblastine and methotrexate  2 CR, 5 PR,  
1 MR 
NR NR 
Okuno and 
Edmonson 
2003 [7] 
07 cyclophosphamide  600  mg/m2 and  
doxorubicin 60 mg/m2; mitomycin  
8 mg/m2, doxorubicin 40 mg/m2, and 
cisplatin 60 mg/m2; ifosfamide 2,500 
mg/m2 and etoposide 100 mg/m2 
Objective  
disease  
regression 
3 patients,  
clinical benefit  
6 patients 
3–12 
months 
2–8 cycles 
3 
months–
15 years 
Patel et al. 
1993 [8] 
09 doxorubicin  60–90  mg/m2 and  
dacarbazine 750–1,000 mg/m2 
2 CR, 4 PR,  
1 MR, 2 SD 
5 cycles  28–253 
months 
Gega et al. 
2006 [9] 
07 doxorubicin  20  mg/m2 daily and  
dacarbazine 150 mg/m2 followed by 
meloxicam 10 mg/m2 
3 CR  4 cycles  NR 
Azzarelli et al. 
2001 [10] 
30 methotrexate  30  mg/m2 and  
vinblastine 6 mg/m2 
12 PR, 18 SD  38 cycles  6–96 
months 
Tsukada et al. 
1991 [11] 
08   adriamycin 50 mg/m2 and  
cyclophosphamide 250 mg/m2 and  
vincristine 2 mg/m2 and 5-FU  
275 mg/m2; adriamycin 50 mg/m2 and 
cyclophosphamide 250 mg/m2 and  
dacarbazine 250 mg/m2 or actinomycin D 
2 CR, 1 PR   NR  NR 
Weiss et al. 
1999 [15] 
17  methotrexate 50 mg parenterally once a 
week and vinorelbine 20 mg/m2 weekly 
3 CR, 7 PR,  
2 MR, 3 SD,  
2 PD 
NR NR 
Response evaluation according to Response Evaluation Criteria in Solid Tumours (RECIST): CR = 
complete response; PR = partial response; SD = stable disease; MR = minor response; PD = progressive 
disease; NR = not reported. 
 
 
Table 2. Overview of studies investigating imatinib as treatment of desmoid tumors 
Study No.  of 
patients 
Dose of imatinib   Result 
Chugh et al. 
ASCO 2006 [12] 
51  2 × 300 mg daily  36 patients had either CR, PR, (at 
2 month) or SD (at 4 month) 
Fayette et al. 
ASCO 2007 [13]  
40  400 mg daily, (increased 
to 800 mg daily if 
progression) for one year 
after 3 month: 1 CR, 3 PR, 31 SD, 
13 PD 
after 13.8 month: 13 PD, 
1 patient died 
Response evaluation according to Response Evaluation Criteria in Solid Tumours 
(RECIST): CR = complete response; PR = partial response; SD = stable disease; MR = minor 
response; NR = not reported. 
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Fig. 1. Clinical presentation and MRI of the patient prior to the treatment (a, d), at the end of 
chemotherapy (b, e) and at the last visit after 18 months of imatinib (c, f). 
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